KR101853997B1 - 빈맥의 치료용 글리코피롤레이트의 용도 - Google Patents

빈맥의 치료용 글리코피롤레이트의 용도 Download PDF

Info

Publication number
KR101853997B1
KR101853997B1 KR1020137025861A KR20137025861A KR101853997B1 KR 101853997 B1 KR101853997 B1 KR 101853997B1 KR 1020137025861 A KR1020137025861 A KR 1020137025861A KR 20137025861 A KR20137025861 A KR 20137025861A KR 101853997 B1 KR101853997 B1 KR 101853997B1
Authority
KR
South Korea
Prior art keywords
tachycardia
composition
glycopyrrolate
heart rate
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020137025861A
Other languages
English (en)
Korean (ko)
Other versions
KR20140020950A (ko
Inventor
수잔 스나이프
로버트 탠슬리
Original Assignee
소세이 리서치 앤드 디벨롭먼트 리미티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45841526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR101853997(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB1103770.2A external-priority patent/GB201103770D0/en
Priority claimed from GBGB1202256.2A external-priority patent/GB201202256D0/en
Application filed by 소세이 리서치 앤드 디벨롭먼트 리미티드 filed Critical 소세이 리서치 앤드 디벨롭먼트 리미티드
Publication of KR20140020950A publication Critical patent/KR20140020950A/ko
Application granted granted Critical
Publication of KR101853997B1 publication Critical patent/KR101853997B1/ko
Assigned to 헵테얼즈 테라퓨틱스 리미티드 reassignment 헵테얼즈 테라퓨틱스 리미티드 권리의 전부이전등록 Assignors: 소세이 리서치 앤드 디벨롭먼트 리미티드
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0028—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up
    • A61M15/0045—Inhalators using prepacked dosages, one for each application, e.g. capsules to be perforated or broken-up using multiple prepacked dosages on a same carrier, e.g. blisters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/009—Inhalators using medicine packages with incorporated spraying means, e.g. aerosol cans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/06—Solids
    • A61M2202/064—Powder

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
KR1020137025861A 2011-03-04 2012-03-05 빈맥의 치료용 글리코피롤레이트의 용도 Active KR101853997B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1103770.2 2011-03-04
GBGB1103770.2A GB201103770D0 (en) 2011-03-04 2011-03-04 Novel use
GB1202256.2 2012-02-09
GBGB1202256.2A GB201202256D0 (en) 2012-02-09 2012-02-09 Novel use
PCT/GB2012/050478 WO2012120284A1 (en) 2011-03-04 2012-03-05 Use of glycopyrrolate for treating tachycardia

Publications (2)

Publication Number Publication Date
KR20140020950A KR20140020950A (ko) 2014-02-19
KR101853997B1 true KR101853997B1 (ko) 2018-05-02

Family

ID=45841526

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020137025861A Active KR101853997B1 (ko) 2011-03-04 2012-03-05 빈맥의 치료용 글리코피롤레이트의 용도

Country Status (20)

Country Link
US (2) US20140080890A1 (https=)
EP (1) EP2680841B2 (https=)
JP (1) JP6129081B2 (https=)
KR (1) KR101853997B1 (https=)
CN (1) CN103501781B (https=)
AR (1) AR085616A1 (https=)
AU (1) AU2012226608B2 (https=)
BR (1) BR112013022523A2 (https=)
CA (1) CA2828640C (https=)
CL (1) CL2013002542A1 (https=)
EA (1) EA025287B1 (https=)
ES (1) ES2613754T5 (https=)
GE (1) GEP201706640B (https=)
IL (1) IL227972A (https=)
JO (1) JO3510B1 (https=)
MD (1) MD4369C1 (https=)
MX (1) MX356025B (https=)
TW (1) TWI536988B (https=)
WO (1) WO2012120284A1 (https=)
ZA (1) ZA201306130B (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8815258B2 (en) 2009-05-29 2014-08-26 Pearl Therapeutics, Inc. Compositions, methods and systems for respiratory delivery of two or more active agents
PL3111927T3 (pl) 2009-05-29 2020-06-29 Pearl Therapeutics, Inc. Kompozycje do wziewnego podawania środków aktywnych oraz związane z nimi sposoby i systemy
AU2013100009B4 (en) * 2013-01-04 2013-03-14 Novartis Ag Treatment of chronic obstructive pulmonary disease
AU2013100007B4 (en) * 2013-01-04 2013-05-23 Novartis Ag System for treating chronic obstructive pulmonary disease
SG11201507286QA (en) 2013-03-15 2015-10-29 Pearl Therapeutics Inc Methods and systems for conditioning of particulate crystalline materials
DK3689332T3 (da) 2014-09-09 2026-03-23 Vectura Ltd Formulering, som omfatter glycopyrrolat, fremgangsmåde og apparat
BR112017009315A2 (pt) * 2014-11-05 2017-12-19 Glenmark Pharmaceuticals Ltd composição de pó seco farmacêutico inalável, processo para preparar uma composição de pó seco farmacêutico inalável, e, método para tratar transtornos respiratórios.
EP3689339B1 (en) 2015-09-09 2022-01-26 Vectura Limited Jet milling method
PL3248646T3 (pl) * 2016-05-25 2021-08-16 Claudia Mattern Dwuczęściowy zestaw półfabrykatu z tworzywa sztucznego
PT109445B (pt) * 2016-06-08 2018-11-06 Hovione Farm Sa Co-cristais farmacêuticos cristalinos de brometo de glicopirrónio com lactose
WO2018167180A1 (en) * 2017-03-15 2018-09-20 Vectura Limited Method and formulation
KR102669919B1 (ko) * 2019-07-10 2024-05-28 한미약품 주식회사 흡입용 캡슐제 및 이의 제조방법

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107872A2 (en) 2004-05-10 2005-11-17 Sosei R&D Ltd. Treating respiratory diseases with gycopyrrolate and analogues
WO2005107873A2 (en) 2004-05-10 2005-11-17 Sosei R&D Ltd. Glycopyrrolate for treating childhood asthma
WO2008000482A1 (en) 2006-06-30 2008-01-03 Novartis Ag Compositions of glycopyrronium salt for inhalation

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2956062A (en) 1959-02-26 1960-10-11 Robins Co Inc A H Esters of amino alcohols
BE718438A (https=) * 1967-08-23 1968-12-31
NL8104929A (nl) * 1980-11-12 1982-06-01 Alza Corp Anticholinergische preparaten, alsmede de bereiding en de toepassing ervan.
GB9501841D0 (en) * 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
EP0909163A4 (en) * 1996-07-01 1999-06-09 Sepracor Inc METHOD AND MEANS FOR TREATING URINE INCONTINENCE USING THE (S, R) -GLYCOPYRROLATE ENANTIOMER MAINLY
GB9808470D0 (en) * 1998-04-22 1998-06-17 Smithkline Beecham Plc Novel process and apparatus
KR20000013487A (ko) * 1998-08-10 2000-03-06 정주영 글리코피롤레이트를 유효성분으로 하는 근시예방 및 치료용 조성물
PL200941B1 (pl) 1998-11-13 2009-02-27 Jagotec Ag Suchy proszkowy preparat inhalacyjny
GB9826286D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
GB9826284D0 (en) 1998-12-01 1999-01-20 Rhone Poulence Rorer Limited Process
DE19921693A1 (de) * 1999-05-12 2000-11-16 Boehringer Ingelheim Pharma Neuartige Arzneimittelkompositionen auf der Basis von anticholinergisch wirksamen Verbindungen und ß-Mimetika
DE10136404A1 (de) * 2001-07-26 2003-02-20 Johannes Wohlrab Arzneiformulierung zur topischen Anwendung für die Therapie und Prophylaxe von Hyperhidrosis
CA2384922C (en) * 2002-05-03 2008-09-02 Purepharm Inc. Topical glycopyrrolate product for the reduction of sweating
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
ES2309705T3 (es) 2004-02-06 2008-12-16 MEDA PHARMA GMBH & CO. KG Nueva combinacion de anticolinergico y beta-mimeticos para el tratamiento de enfermedades respiratorias.
GB0409703D0 (en) * 2004-04-30 2004-06-02 Vectura Ltd Pharmaceutical compositions
US7923455B2 (en) 2005-01-28 2011-04-12 Boehringer Ingelheim International Gmbh Medicaments for the prevention or treatment of heart failure comprising administration of an anticholinergic
EP1894568A1 (en) 2006-08-31 2008-03-05 Novartis AG Pharmaceutical compositions for the treatment of inflammatory or obstructive airway diseases
GB0703999D0 (en) * 2007-03-01 2007-04-11 Astrazeneca Ab New combination 667
US20080260823A1 (en) * 2007-04-20 2008-10-23 Sciele Pharma, Inc. Orally disintegrating tablet comprising glycopyrrolate for treating sialorrhea
US20100055045A1 (en) 2008-02-26 2010-03-04 William Gerhart Method and system for the treatment of chronic obstructive pulmonary disease with nebulized anticholinergic administrations
AU2010258751A1 (en) 2009-06-09 2012-02-02 Sunovion Respiratory Development Inc. Treatment of chronic obstructive pulmonary disease with nebulized beta 2-agonist or combined nebulized beta 2-agonist and anticholinergic administration

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005107872A2 (en) 2004-05-10 2005-11-17 Sosei R&D Ltd. Treating respiratory diseases with gycopyrrolate and analogues
WO2005107873A2 (en) 2004-05-10 2005-11-17 Sosei R&D Ltd. Glycopyrrolate for treating childhood asthma
WO2008000482A1 (en) 2006-06-30 2008-01-03 Novartis Ag Compositions of glycopyrronium salt for inhalation

Also Published As

Publication number Publication date
IL227972A (en) 2017-06-29
TW201247198A (en) 2012-12-01
US20140080890A1 (en) 2014-03-20
AR085616A1 (es) 2013-10-16
ZA201306130B (en) 2014-04-30
EP2680841A1 (en) 2014-01-08
US10695321B2 (en) 2020-06-30
MX2013009838A (es) 2016-09-27
JP6129081B2 (ja) 2017-05-17
KR20140020950A (ko) 2014-02-19
CA2828640C (en) 2017-01-03
US20160143880A1 (en) 2016-05-26
MD4369B1 (ro) 2015-09-30
JO3510B1 (ar) 2020-07-05
EP2680841B2 (en) 2025-10-22
CA2828640A1 (en) 2012-09-13
JP2014514271A (ja) 2014-06-19
AU2012226608A1 (en) 2013-09-12
IL227972A0 (en) 2013-09-30
ES2613754T5 (en) 2026-01-22
CN103501781A (zh) 2014-01-08
MD4369C1 (ro) 2016-04-30
BR112013022523A2 (pt) 2016-11-29
EA025287B1 (ru) 2016-12-30
MX356025B (es) 2018-05-09
WO2012120284A1 (en) 2012-09-13
CN103501781B (zh) 2016-10-26
ES2613754T3 (es) 2017-05-25
AU2012226608B2 (en) 2015-11-26
MD20130069A2 (ro) 2014-03-31
NZ614603A (en) 2016-01-29
TWI536988B (zh) 2016-06-11
EP2680841B1 (en) 2016-12-28
CL2013002542A1 (es) 2014-07-11
EA201391275A1 (ru) 2014-02-28
GEP201706640B (en) 2017-03-27

Similar Documents

Publication Publication Date Title
KR101853997B1 (ko) 빈맥의 치료용 글리코피롤레이트의 용도
AU2011200543B2 (en) Pharmaceutical compositions
JP2004500429A (ja) チオトロピウム及びロフレポニドを含む医薬用の組み合わせ
JP2015519394A (ja) キシナホ酸サルメテロール、プロピオン酸フルチカゾンおよび臭化チオトロピウムを含む吸入製剤用ドライパウダー、ならびにその製造方法
US20050053553A1 (en) Combined doses of formoterol and fluticasone
JP2004529108A (ja) Ｒ−サルメテロールおよびプロピオン酸フルチカゾンを含んでなる医薬製剤
CA2529127A1 (en) Combined doses of tiotropium and fluticasone
AU2021200396A1 (en) Pharmaceutical composition containing budesonide and formoterol
HK1188393B (en) Use of glycopyrrolate for treating tachycardia
HK1188393A (en) Use of glycopyrrolate for treating tachycardia
NZ614603B2 (en) Use of glycopyrrolate for treating tachycardia
JP2004500436A (ja) 呼吸器用組成物
HK1095282B (en) Methods for preparing dry powder compositions of glycopyrrolate
HK1168273A (en) Methods for preparing dry powder compositions of glycopyrrolate
HK1167334B (en) Dry powder compositions of glycopyrrolate and magnesium stearate

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E90F Notification of reason for final refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R14-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 8

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 9

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 9